Abstracts tagged "Biologic agents"

Abstract Number: 1674 • 2016 ACR/ARHP Annual Meeting
Do TNF Inhibitors Change the Progression of Sacroiliitis?
Deeba Minhas¹, MinJae Lee^2,3, Mohammad H. Rahbar³, Lianne S. Gensler⁴, John D. Reveille⁵ and Michael Weisman¹, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Medicine, University of Texas Health Science Center at Houston, Houston, TX, ³Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁴Medicine/Rheumatology, UCSF, San Francisco, CA, ⁵Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory arthritis affecting the sacroiliac (SI) joints and spine causing structural changes seen on clinical radiography. Studies have…
Abstract Number: 2343 • 2016 ACR/ARHP Annual Meeting
A Phase 2, Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group Study to Evaluate the Safety and Dose Effectiveness of Intradermal Injections of Purified Apis Mellifera Toxin to Improve Pain and Physical Function in Patients with Osteoarthritis of the Knee
Douglas R. Schumacher¹, Anna Jakubowska² and Christopher M.H. Kim³, ¹Radiant Research, Columbus, OH, ²Apimeds, Inc., Jungwongu, Seongnam, Gyeonggido, Korea, The Republic of, ³CHA University, Bundanggu, Seongnam, Gyeongghido, Korea, The Republic of
Background/Purpose: This Phase 2a/b trial evaluated the safety and dose effectiveness of honeybee toxin (purified Apis melliferatoxin) injections to improve pain and physical function in…
Abstract Number: 2669 • 2016 ACR/ARHP Annual Meeting
Biological Treatments in Primary SjöGren Syndrome
Monica Fernandez Castro¹, Jose Luis Andreu², Carlos Sánchez-Piedra³, Víctor Martínez Taboada⁴, Alejandro Olivé⁵, José Rosas⁶, Raúl Menor Almagro⁷, Beatriz Rodriguez Lozano⁸, Angel Garcia-Aparicio⁹, Francisco Javier López Longo¹⁰, Sara Manrique-Arija¹¹, Jesus Alberto Garcia Vadillo¹², Susana Gil Barato¹³, Ruth Lopez Gonzalez¹⁴, Javier Narváez¹⁵, Carlos Galisteo¹⁶ and on behalf of Sjogren-SER project (GEEAS-SER), ¹Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ²Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ³Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain, ⁴Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁶Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁷Rheumatology, Hospital General de Jerez de la Frontera, Jerez de la Frontera, Spain, ⁸Rheumatology, Hospital de Canarias, S/C Tenerife, Spain, ⁹Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ¹⁰Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ¹¹Rheumatology, Hospital Carlos Haya, Malaga, Spain, ¹²Rheumatology, Hospital La Princesa, Madrid, Spain, ¹³Rheumatology, Hospital General de Alicante, Alicante, Spain, ¹⁴Rheumatology, Hospital Virgen de la Concha, Salamanca, Spain, ¹⁵Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ¹⁶Rheumatology, Hospital Parc-Taulí, Sabadell, Spain
Background/Purpose: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease involving mainly the exocrine glandular system. Nevertheless, its clinical spectrum includes the development of multiple…
Abstract Number: 628 • 2016 ACR/ARHP Annual Meeting
Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice
M. Victoria Hernández¹, Carlos Sánchez-Piedra², Juan D. Cañete¹, Fernando Sanchez-Alonso², Javier Manero³, Ana M. Ortiz Garcia⁴, Eva Pérez-Pampin⁵, Rosa Roselló⁶, Carlos Rodriguez-Lozano⁷, Raimon Sanmarti¹, Juan J. Gómez-Reino⁵ and BIOBADASER 2.0 Study Group, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁵Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, ⁶Rheumatology, H San Jorge, Huesca, Spain, ⁷Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
Background/Purpose: Currently, the most widely used biological agents for rheumatoid arthritis (RA) patients are the inhibitors of the tumor necrosis factor (TNFi), although other biological…
Abstract Number: 1682 • 2016 ACR/ARHP Annual Meeting
Tnfα Inhibitors Are Associated with Reduced Progression of Carotid Atherosclerotic Plaques By Ultrasound and an Improvement in Aortic Arch Vascular Inflammation By 18-FDG PET/CT in Psoriasis and Psoriatic Arthritis Patients – a Prospective Study from Two Cohorts
Lihi Eder¹, Aditya Joshi², Vinod Chandran³, Amit Dey⁴, Richard J. Cook⁵, Abhishek Chaturvedi⁶, Dafna D. Gladman⁷ and Nehal Mehta⁸, ¹Medicine, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴National Institutes of Health, Bethesda, MD, ⁵Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁶National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ⁷Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁸National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Psoriasis (PSO) and psoriatic arthritis (PsA) are chronic inflammatory diseases which are associated with increased cardiovascular (CV) diseases. Observational studies have found that TNFα…
Abstract Number: 2375 • 2016 ACR/ARHP Annual Meeting
Biologic Therapy Modifies Clinical and Laboratory Features of Macrophage Activation Syndrome Associated with Systemic Juvenile Idiopathic Arthritis
Grant Schulert¹, Francesca Minoia², John F. Bohnsack³, Randy Q. Cron⁴, Soah Hashad⁵, Isabelle Koné-Paut⁶, Mikhail Kostik⁷, Daniel J Lovell⁸, Despoina Maritsi⁹, Peter A. Nigrovic¹⁰, Priyankar Pal¹¹, Angelo Ravelli², Masaki Shimizu¹², Valda Stanevicha¹³, Bas Vastert¹⁴, Fabrizio De Benedetti¹⁵ and Alexei Grom¹⁶, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto Giannina Gaslini, Genoa, Italy, ³Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁴Pediatric Rheumatology, Children's Hospital of Alabama, Birmingham, AL, ⁵Tripoli Children's Hospital, Tripoli, Libya, ⁶Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁷Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ⁸PRCSG Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁹2nd Department of Academic Pediatrics, Athens Medical School, university of Athens, Athens, Greece, ¹⁰Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA, ¹¹Institute of Child Health, Kolkata, India, ¹²Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan, ¹³Pediatric cathedra, Riga Stradiņš University, Riga, Latvia, ¹⁴Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands, ¹⁵Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening episode of hyperinflammation and a substantial cause of morbidity and mortality in pediatric rheumatology. It occurs most…
Abstract Number: 2688 • 2016 ACR/ARHP Annual Meeting
Characteristics, Treatment and Outcome of Joint Involvement with Synovitis in Primary SjöGren’s Syndrome: French Multicentric Retrospective Case-Control Study
Adrien Mirouse¹, raphaèle seror², Xavier Mariette³, Maxime Dougados⁴, Anne-Laure Fauchais⁵, Alban Deroux⁶, Nathalie Costedoat-Chalumeau⁷, Jeremie Sellam⁸, Jean-Benoit Arlet⁹, Christian Lavigne¹⁰, Dominique Fischer-Dumont¹¹, Arsène Mékinian¹² and Olivier Fain¹², ¹Service de médecine interne, Hôpital Saint-Antoine, Paris, France, ²INSERM U1184, Paris Sud University, Le Kremlin Bicetre, France, ³INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France, ⁴Paris Descartes University, Paris, France, ⁵Department of Internal Medicine, CHU de Limoges, Limoges, France, ⁶Internal Medicine, CHU Grenoble, Grenoble, France, ⁷Internal Medicine, Cochin University Hospital, Paris, France, ⁸Rheumatology, Saint-Antoine Hospital, Paris, France, ⁹Service de médecine interne, Hopital Européen Georges Pompidou, Paris, France, ¹⁰CHU Angers, department of Internal Medicine, Angers, France, ¹¹Service de rhumatologie, Hôpital Avicenne, Bobigny, France, ¹²Service de médecine interne. Hôpital Saint-Antoine., Paris, France
Background/Purpose: primary Sjogren’s syndrome (pSS) articular manifestations include often tender joints and more rarely synovitis. The main objective of this study was to describe characteristics,…
Abstract Number: 765 • 2016 ACR/ARHP Annual Meeting
High Baseline B Lymphocyte Stimulator (BLyS) Levels Predict Response While Smoking and Organ Damage at Baseline Predict Failure to Belimumab in Three Swedish Clinical Practice Settings
Ioannis Parodis¹, Christopher Sjöwall², Andreas Jönsen³, Agneta Zickert¹, Daniel Ramsköld¹, Martina Frodlund², Laurent Arnaud¹, Vivianne Malmström¹, Anders A. Bengtsson³ and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ³Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden
Background/Purpose: Belimumab is a biologic drug approved to treat Systemic Lupus Erythematosus (SLE). The efficacy of belimumab has been demonstrated in phase III clinical trials.…
Abstract Number: 1717 • 2016 ACR/ARHP Annual Meeting
Progression of Radiographic Axial Damage in Patients with Psoriatic Arthritis. Relation with Clinical and Analytical Factors
Alba Quesada-Moreno¹, Maria Dolores Sanchez-González², Laura Pérez-Garrido³, Ricardo Usategui-Martín⁴, Guadalupe Manzano-Canabal¹, Cristina Hidalgo-Calleja¹, Olga Martínez-González¹, Javier Del Pino-Montes¹ and Carlos Alberto Montilla-Morales¹, ¹Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ²HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ³Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, SALAMANCA, Spain, ⁴IBSAL, SALAMANCA, Spain
Background/Purpose: Axial involvement in psoriatic arthritis (PsA) is a controversial issue. Lack of unanimity in the definition has led to a wide range of…
Abstract Number: 2478 • 2016 ACR/ARHP Annual Meeting
Impact of Poor Prognostic Factors on Treatment Decisions in Clinical Practice in Patients with Rheumatoid Arthritis: Findings from a US Observational Cohort
LR Harrold¹, E Alemao², HJ Litman³, SE Connolly⁴, S Kelly², W Hua³, L Rosenblatt², S Rebello⁵ and JM Kremer⁶, ¹University of Massachusetts Medical School, Worcester, MA, ²Bristol-Myers Squibb, Princeton, NJ, ³Corrona, Southborough, MA, ⁴Department of Immunology and Inflammation, Bristol-Myers Squibb, Princeton, NJ, ⁵Epidemiology, Corrona, Southborough, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Poor prognostic factors can determine the extent of disease progression, disability and treatment outcomes in patients (pts) with RA. It is currently unknown whether…
Abstract Number: 2743 • 2016 ACR/ARHP Annual Meeting
Do Specific Entheseal Points in Spa Patients Impact Patient Reported Outcomes? Implications for Clinical Practice
John Kelsall¹, Pauline Boulos², Regan Arendse³, Michelle Teo⁴, Anna Jaroszynska⁵, Michael Starr⁶, Alexander Tsoukas⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Karina Maslova¹⁰, Cathy Tkaczyk¹¹, Francois Nantel¹², Brendan Osborne¹¹ and Allen J Lehman¹⁰, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, McMaster University, Hamilton, ON, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ⁵Private practice, Burlington, ON, Canada, ⁶Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ⁷McGill University, Montreal, QC, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have shown associations between swelling or tenderness of specific joints in RA patients and patient pain. This analysis aimed to describe the…
Abstract Number: 770 • 2016 ACR/ARHP Annual Meeting
Introducing a Novel SLE-Specific IFN-I Inhibitor CNTO 6358: Laying the Groundwork for Precision Medicine in Lupus
Jarrat Jordan¹, Matteo Cesaroni¹, Jessica Schreiter¹, Chichi Huang², Tanesha Cash-Mason³, Marc Chevrier¹ and Jacqueline Benson¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Biologics Research, Janssen Research and Development, LLC., Spring House, PA, ³Cardiovascular and Metabolism Research, Janssen Research and Development, LLC., Spring House, PA
Background/Purpose: The type I interferon (IFN-I) family of cytokines signal through a ubiquitously expressed heterodimeric receptor (IFNAR) composed of IFNAR1 and the high-affinity binding chain…
Abstract Number: 1719 • 2016 ACR/ARHP Annual Meeting
Secular Trends in Treatment Patterns for Psoriasis and Psoriatic Arthritis: A Population-Based Cohort Study
Joseph F Merola¹, Joyce Lii², Rishi J. Desai³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medicine, Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are complex, multi-system diseases for which an ever-increasing landscape of therapies exists. Little is known about the population…
Abstract Number: 2491 • 2016 ACR/ARHP Annual Meeting
Is It Possible to Predict Which Patients Treated with Biologic Agents for Rheumatic Diseases Will Develop Anti-Drug Antibodies ?
Pascal Zufferey¹, Melanie Favre dit Jeanfavre², Alexandre Dumusc³, Charles Benaim⁴, Matthieu Perreau⁵ and Alexander K. So Sr.⁶, ¹Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland, ²DAL, RHU, Lausanne, Switzerland, ³DAL, RHU/CHUV, Lausanne, Switzerland, ⁴DAL, MPR, Lausanne, Switzerland, ⁵Medecine /CHUV, Immunology, Lausanne, Switzerland, ⁶Service De Rhumatologie, CHUV, Lausanne, Switzerland
Background/Purpose: All biologic agents (bDMARDs) currently used in rheumatology can induce anti-drug antibodies (ADAB), which will influence the drug levels and the drug effectiveness. Why…
Abstract Number: 2746 • 2016 ACR/ARHP Annual Meeting
Comparing Prevalence of Comorbidities in Patients with Psoriatic Arthritis By Biologic Therapy
Jeffrey Kaine¹, Xue Song², Gilwan Kim² and Jacqueline Palmer³, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Truven Health Analytics, Cambridge, MA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) are known to be at higher risk for numerous comorbid conditions. This study looks at the impact of biologic therapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].